Fed’s Powell opens door to potential rate cuts at Jackson Hole
On Thursday, BTIG reaffirmed its Buy rating and $3.00 price target for iCAD Inc . (NASDAQ:ICAD), following the company’s report of fourth-quarter revenue that exceeded both its preannouncement and consensus estimates. The medical technology company posted revenue of $5.4 million, which was slightly above the projected range of $5.1 million to $5.3 million and higher than the consensus estimate of $4.5 million at the time of the preannouncement. According to InvestingPro data, ICAD has demonstrated impressive momentum with a 59.35% return over the past year, while maintaining strong gross profit margins of 87.51%.
The company achieved a gross margin of 86%, with an adjusted EBITDA of negative $0.5 million and an adjusted loss per share (LPS) of $0.03. In the fourth quarter, iCAD successfully closed 106 deals, including 19 cloud-based deals, demonstrating an increase from the 85 deals closed in the previous quarter, of which 13 were cloud deals. Total (EPA:TTEF) recurring revenue (T-ARR) climbed to $9.8 million, marking an 11% year-over-year growth, and saw a roughly $500,000 sequential increase. InvestingPro analysis reveals the company maintains a healthy financial position with a current ratio of 4.02, indicating strong liquidity to support its growth initiatives. Get access to 10+ additional ProTips and comprehensive financial metrics with InvestingPro.
The T-ARR was composed of approximately $6.4 million from Maintenance Services ARR, around $2.6 million from Subscription ARR, and nearly $800,000 from Cloud ARR. Despite the strong quarter, the management highlighted that the results were favorably influenced by the timing of certain deals, which had been anticipated in either the third quarter or the first quarter of the next year.
iCAD’s ProFound Detection v4.0, which received FDA clearance in November, has been deployed in the field for about a quarter and is reportedly showing better accuracy in practice than in clinical studies. The company has also completed presubmission work for its Breast Arterial Calcification (BAC) and is aiming for FDA approval within 2025. Additionally, iCAD is planning to submit Profound Risk for approval next year.
The transition to a recurring revenue model for iCAD is expected to be gradual, and while the sequential increase in cloud deals is viewed positively, BTIG anticipates near-term variability in revenue due to the lower initial revenue from the shift to this model. The firm projects sales growth to be roughly flat year-over-year in 2025, with a 10% year-over-year increase in 2026. The reaffirmed $3 price target is based on a 3x EV/Sales valuation multiple applied to BTIG’s revenue forecast for the next 12 to 24 months. InvestingPro’s Fair Value analysis suggests the stock is currently trading near its intrinsic value, with a P/B ratio of 2.22 and revenue growth of 10.03% over the last twelve months. Discover the complete financial story with InvestingPro’s comprehensive research report, available for 1,400+ US stocks.
In other recent news, iCAD Inc. reported its fourth-quarter 2024 earnings, showing a significant improvement with an earnings per share (EPS) of -$0.03, which exceeded the forecasted -$0.06. The company’s revenue reached $5.41 million, surpassing expectations of $4.5 million. This revenue growth was attributed to a 24% year-over-year increase in product sales. iCAD is transitioning to a Software-as-a-Service (SaaS) model, which is anticipated to enhance revenue predictability. The company’s gross profit margin decreased to 86% from 91% the previous year. Analysts from BTIG noted the company’s strong performance and the impact of its SaaS transition on revenue recognition. iCAD closed a total of 106 deals in the fourth quarter, including 19 cloud deals, reflecting a growing adoption of its cloud-based solutions. The company also secured new partnerships, expanding its commercial opportunities in North America and globally.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.